Sangamo Therapeutics Announces New Scientific Advisory Board

BRISBANE, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that is has established a new Scientific Advisory Board (SAB). The SAB comprises an eclectic group of industry and academic experts who will advise Sangamo on its current and future clinical programs and research and development strategy. “I am excited to be working with such a distinguished, diverse, and imaginative group of experts who have joined our Scientific Advisory B

Click to view original post